Class denied for brand loyalty

A federal judge on Tuesday said that lawyers representing the buyers of two cancer drugs must sort out which buyers would not have switched to a generic version of the medication because of brand loyalty before she would grant those plaintiffs class certification.

Get unlimited access to all Global Competition Review content